Industry News (Patents and Technology)

Allowance of Fibroblast Patent in U.S. Announced

Published in Gene Therapy Weekly, November 13th, 1995

Somatix Therapy Corp., Alameda, California, announced that the U.S. Patent Office has granted a patent for genetically modified fibroblasts, or skin cells.

The patent, No. 5,460,959 was filed by the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (MIT), and was exclusively licensed to Somatix in 1988. A European patent was granted on the corresponding European application in January 1995.

The patent's claims are broad, covering the use of retrovirally transduced human fibroblasts bound to a support matrix.

Fibroblasts have been identified over the course of Somatix's preclinical work as having...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry